Weight Management

Hims & Hers launches Wegovy knockoff pill in U.S., Novo Nordisk vows to sue
Telehealth company Hims & Hers said Thursday it will launch a cheaper, off-brand version of the weight-loss pill Wegovy, just weeks after drugmaker Novo Nordisk launched its highly anticipated reformulation of the blockbuster medication.
U.S. FDA says popular weight-loss drugs shouldn't carry suicide warnings
Labeling for other drugs known as GLP-1 receptor agonists approved to treat diabetes carried no such warnings, the agency noted.

What is ‘food noise’ and why are we hearing about it amid the rise of GLP-1 meds?

The term ‘food noise’ has emerged alongside the popularity of glucagon-like peptide-1 receptor agonists—known as GLP-1 medications—that treat Type 2 diabetes and obesity.
2025 was the year protein ‘jumped the shark’

Thirty years ago, when I began studying protein metabolism, I would never have guessed that 2025 would be spent explaining why more protein is not always better.
Finding your niche: Obesity management

Two pharmacists pursue different paths to make weight-management a key part of their practice.
GLP-1 RAs are increasingly being used to lose weight after childbirth

New study provides contemporary data on the frequency of glucagon-like peptide 1 receptor agonist use for postpartum weight reduction.
Weight loss interventions can cause new skin issues to crop up for your patients

Paradoxically, bariatric surgery is sometimes responsible for the development of new pathologies.
Obesity: Why do so many patients abandon GLP-1 agonists?

Despite the hype surrounding GLP-1 receptor agonists, a significant proportion of patients discontinue treatment after a few months, reducing the chances of long-term benefits.
Following healthy food guidelines in Canada comes at a high cost, study finds

A recent study out of Laval University finds many foods that are high in sodium and sugar on Canadian shelves are much cheaper than healthier, equivalent options.
A pill to treat obesity?

Orforglipron, a GLP-1 receptor agonist in tablet form, has proven effective in treating obesity in a phase 3 trial, offering a potential alternative to injectable treatments like Wegovy and Ozempic.

Hims & Hers launches Wegovy knockoff pill in U.S., Novo Nordisk vows to sue

U.S. FDA says popular weight-loss drugs shouldn't carry suicide warnings

What is ‘food noise’ and why are we hearing about it amid the rise of GLP-1 meds?

2025 was the year protein ‘jumped the shark’

Finding your niche: Obesity management

GLP-1 RAs are increasingly being used to lose weight after childbirth

Weight loss interventions can cause new skin issues to crop up for your patients

Obesity: Why do so many patients abandon GLP-1 agonists?

Following healthy food guidelines in Canada comes at a high cost, study finds

A pill to treat obesity?